Evidence map›Paper›PMID 41815287›Full record

ArticleBlood neoplasia2026

Synergistic targeting of eIF4A-mediated translation initiation and apoptosis in acute myeloid leukemia.

Yoke Seng Lee, Jonathan D Good, Noha Awais, Benjamin K Eschle, Maia S Lineberry, Jingting Lin, Mark Wunderlich, Jenna Thibodeau, Holly Edwards, Jessica L Teo and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Yoke Seng LeeDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Jonathan D GoodDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Noha AwaisDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Benjamin K EschleDana-Farber Cancer Institute, Boston, MA.
Maia S LineberryDana-Farber Cancer Institute, Boston, MA.
Jingting LinDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Mark WunderlichCincinnati Children's Hospital Medical Center, Cincinnati, OH.
Jenna ThibodeauCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI.
Holly EdwardsMolecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI.
Jessica L TeoDepartment of Biomedical Engineering, Boston University, Boston, MA.
Sarah BibeauDepartment of Biology, Boston College, Chestnut Hill, MA.
Morgan WollmanDepartment of Human Biology, Sattler College, Boston, MA.
George KaradimovDepartment of Biology, Boston College, Chestnut Hill, MA.
Nurefsan SariipekDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Basit SalikDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Jean AcostaDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Jenny NoelDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
David G J CucchiDepartment of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Erica A K DePasqualeDivision of Hematology, Brigham and Women's Hospital, Boston, MA.
Prafulla C GokhaleDana-Farber Cancer Institute, Boston, MA.
Jerome RitzDepartment of Medicine, Harvard Medical School, Boston, MA.
Yubin GeCancer Biology Graduate Program, Wayne State University School of Medicine, Detroit, MI.
Peter G MillerDepartment of Medicine, Harvard Medical School, Boston, MA.
Fadi J NajmBroad Institute of MIT and Harvard, Cambridge, MA.
Richard M StoneDepartment of Medicine, Harvard Medical School, Boston, MA.
Jacqueline S GarciaDepartment of Medicine, Harvard Medical School, Boston, MA.
Andrew A LaneDepartment of Medicine, Harvard Medical School, Boston, MA.
Courtney L JonesCincinnati Children's Hospital Medical Center, Cincinnati, OH.
Peter van GalenDivision of Hematology, Brigham and Women's Hospital, Boston, MA.

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Therapeutic insights through patient derived leukemia xenograftsR50CA211404 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Mark Wunderlich · 2016 to 2026
$1.9M
Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem CellsR37CA291896 · NCI · CINCINNATI CHILDRENS HOSP MED CTR · PI Courtney Lynn Jones · 2025 to 2026
$1.1M
NCI NIH HHS P01 CA066996NCI NIH HHS R37 CA291896NCI NIH HHS R50 CA211404
6 · The paper itself

Abstract

Targeted therapies, such as the BCL-2 inhibitor venetoclax, have expanded the treatment options for patients with acute myeloid leukemia (AML), but survival remains poor because of drug resistance and disease relapse. We found that the translation initiation factor

Identifiers

PMID41815287
PMCPMC12971725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.